Biopatch (trademark) or Kendall (trademark) AMD Foam Disc to reduce the incidence of Central-Line-Associated Blood Stream Infection: A pilot randomized controlled trial
Phase 2
Completed
- Conditions
- Central catheter related blood stream infectionInfection - Studies of infection and infectious agents
- Registration Number
- ACTRN12615000883516
- Lead Sponsor
- Royal Brisbane and Womens Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients who are 16 years of age or older
Requiring a central catheter for at least three days
No previous central catheter this admission
Informed consent to participate
Central venous catheter inserted in Department of Medical Imaging, the Wattlebrae Day Therapy Unit or ICU
Exclusion Criteria
Current bloodstream infection
Non-English speakers without interpreter
Previous enrolment in the current study
Known allergy to chlorhexidine or PHMB
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method aboratory confirmed number of central line associated blood stream infections (CLABSI) per 10,000 line-days. Diagnosis will be made based on a presence of a bloodstream infection that is not secondary to an infection at another body site and where a central line has been in place for >2 days. [Daily monitoring for CLABSI from time of central line insertion until time of central line removal.]
- Secondary Outcome Measures
Name Time Method